semaglutide stimulant is a medication typically prescribed for Type 2 diabetes; however, it has gained recent popularity as a weight-loss medication. Learn more from Bryan Kuhn, PharmD, DABAT, Clinical Educator at the Banner Semaglutide Oral | Starts at

The NF-kB pathway: ground zero for autoimmune inflammation Nuclear factor kappa B, or NF-kB, is the master switch for inflammatory gene expression

Research has shown potential reductions in: Serious heart problems by 14% Death from any cause by 12% Hospitalization for heart failure by 14% Serious kidney problems by 17% Current Research Current studies are exploring: Improved dosing strategies Long-term risks and benefits of multi-year use Future Research Researchers are studying: Triple agonist medications Whether oral pills are as effective as injections Clinical Trials Participants typically receive: A health screening No-cost participation Medical support throughout the study Yes

Notably, disulfide bonds at Cys149-Cys189 and Cys177-Cys201 residues could be potential targets of LASSS modification/remodeling

[Epub ahead of print] Vo NX, Le NNH, Chu TDP, et al

Once symptoms improve and kidney function stabilizes, the treatment can be restarted at a lower dose, with gradual increases as tolerated